Patents by Inventor Maher Qabar
Maher Qabar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11938191Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: May 1, 2020Date of Patent: March 26, 2024Assignee: GENEVANT SCIENCES GMBHInventors: Sean D. Monahan, Michael S. Declue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Publication number: 20210023235Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: May 1, 2020Publication date: January 28, 2021Applicant: GENEVANT SCIENCES GMBHInventors: Sean D. MONAHAN, Michael S. DeCLUE, Pierrot HARVIE, Russell N. JOHNSON, Amber E. PASCHAL, Mary G. PRIEVE, Debashish ROY, Charbel DIAB, Michael E. HOUSTON, JR., Anna GALPERIN, Maher QABAR
-
Patent number: 10660970Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: August 16, 2019Date of Patent: May 26, 2020Assignee: Genevant Sciences GmbHInventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Patent number: 10646582Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: November 30, 2017Date of Patent: May 12, 2020Assignee: Genevant Sciences GmbHInventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Publication number: 20190388551Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: August 16, 2019Publication date: December 26, 2019Applicant: GENEVANT SCIENCES GMBHInventors: Sean D. MONAHAN, Michael S. DeCLUE, Pierrot HARVIE, Russell N. JOHNSON, Amber E. PASCHAL, Mary G. PRIEVE, Debashish ROY, Charbel DIAB, Michael E. HOUSTON, Anna GALPERIN, Maher QABAR
-
Publication number: 20180243433Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: November 30, 2017Publication date: August 30, 2018Inventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, JR., Anna Galperin, Maher Qabar
-
Patent number: 9867885Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: July 30, 2014Date of Patent: January 16, 2018Assignee: PhaseRx, Inc.Inventors: Sean D Monahan, Michael S Declue, Pierrot Harvie, Russell N Johnson, Amber E Paschal, Mary G Prieve, Debashish Roy, Charbel Diab, Michael E Houston, Jr., Anna Galperin, Maher Qabar
-
Publication number: 20160206750Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: ApplicationFiled: July 30, 2014Publication date: July 21, 2016Inventors: Sean D MONAHAN, Michael S DECLUE, Pierrot HARVIE, Russell N JOHNSON, Amber E PASCHAL, Mary G PRIEVE, Debashish ROY, Charbel DIAB, Michael E HOUSTON, Jr., Anna GALPERIN, Maher QABAR
-
Patent number: 7829737Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.Type: GrantFiled: March 6, 2008Date of Patent: November 9, 2010Assignee: Ceptyr, Inc.Inventors: Mark Arnold Thomas Blaskovich, Ted Baughman, Thomas Little, Maher Qabar, Lauri Marie Schultz, Feng Hong, William Patt, Gangadhar Nagula, Jennifer Lynn Gage, James Jeffry Howbert
-
Publication number: 20090131374Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.Type: ApplicationFiled: January 30, 2009Publication date: May 21, 2009Applicant: CEPTYR, INC.Inventors: Mark Arnold Thomas Blaskovich, Ted Baughman, Thomas Little, William Patt, Maher Qabar, Lauri Marie Schultz, Feng Hong, Gangadhar Nagula, Jennifer Lynn Gage, James Jeffry Howbert
-
Patent number: 7504389Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.Type: GrantFiled: November 15, 2005Date of Patent: March 17, 2009Assignee: Ceptyr, Inc.Inventors: Mark Arnold Thomas Blaskovich, Ted Baughman, Thomas Little, William Patt, Maher Qabar, Lauri Mario Schultz, Gangadhar Nagula, Jennifer Lynn Gage, James Jeffry Howbert
-
Publication number: 20080161592Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.Type: ApplicationFiled: March 6, 2008Publication date: July 3, 2008Applicant: CEPTYR, INC.Inventors: Mark Arnold Thomas Blaskovich, Ted Baughman, Thomas Little, William Patt, Maher Qabar, Lauri Marie Schultz, Feng Hong, Gangadhar Nagula, Jennifer Lynn Gage, James Jeffrey Howbert
-
Publication number: 20060293372Abstract: ?-sheet mimetics and methods relating to the same are disclosed. The ?-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a ?-sheet mimetic, or use of the same for the manufacture of a medicament for treatment of a variety of conditions associated with the targeted protease, kinase, transcription factor and/or protein-protein binding interaction.Type: ApplicationFiled: February 5, 2004Publication date: December 28, 2006Applicant: Myriad Genetics, Inc.Inventors: Maher Qabar, Michael McMillan, Michael Kahn, John Tulinsky, Cyprian Ogbu, Jessymol Mathew
-
Publication number: 20060142250Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.Type: ApplicationFiled: November 15, 2005Publication date: June 29, 2006Inventors: Mark Blaskovich, Ted Baughman, Thomas Little, William Patt, Maher Qabar, Lauri Schultz, Feng Hong, Gangadhar Nagula, Jennifer Gage, James Howbert
-
Publication number: 20050250780Abstract: Reverse-turn mimetics and methods relating to the same having the following structure are disclosed: including pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3 and R4 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such compounds, are neurokinin (tachykinin) antagonists. Libraries containing the reverse-turn mimetics of this invention are also disclosed.Type: ApplicationFiled: April 18, 2005Publication date: November 10, 2005Applicant: Myriad Genetics, IncorporatedInventors: Maher Qabar, Marcin Stasiak, Jessymol Mathew, Thomas Little, Danwen Huang